| (L-R) Wulff Niedner, Director of HPLC Marketing, Thermo Fisher Scientific; Andreas Premstaller, Head, Sandoz Pharmaceuticals Schaftenau production site; Prof Christian Huber, Head, new Doppler Laboratory; Alain Guiller, Vice President of Global Sales, Life Science Mass Spectrometry, Thermo Fisher and Kornelia Weidemann, Europe Commercial General Manager, Thermofisher |
The Christian Doppler Laboratory for Biosimilar Characterisation has opened at the Paris-Lodron University of Salzburg, and scientists there have commenced developing new methods for characterising proteins to be used in biopharmaceuticals. The new facility, co-funded by the Austrian Federal Ministry of Economy, Family and Youth, as well as the County of Salzburg through the Christian Doppler Society, was established to develop and transfer to practice novel and more efficient methods to characterise the active ingredients in protein-based medicines. Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific are collaborating in these efforts.
“The more physical, chemical and biological data we can obtain for protein-based drugs, the more certain we can be that they will produce the desired effects and will not produce unexpected adverse effects,” explained Christian Huber, Head of the new Christian Doppler lab. “Here, we are joining expertise in protein production and characterisation, structural biology and synthetic chemistry at the University of Salzburg to develop innovative characterisation tools to determine the efficacy and safety of protein-based medicines,” he added.
“As the leader in protein characterisation technology, we are confident that we will make a significant technical contribution to the detailed analysis of biosimilars and their quality control,” observed Dr Alain Guiller, Vice President of Global Sales, Life Science Mass Spectrometry (LC-MS), Thermo Fisher Scientific. “This is a rapidly-developing field, and this close cooperation with the University of Salzburg and Sandoz will increase our understanding and help us to serve the emerging needs of the pharma industry. Thermo Fisher’s participation will focus on providing expertise for applying Orbitrap-based LC-MS technology, nano-UHPLC (ultra high-perfomance liquid chromatography) systems and columns, and software to future workflows for protein-based drug characterization and quality control.
EP News Bureau – Mumbai